Zanidatamab

• CAT Number: I042217
• CAS Number: 2169946-15-8
• Purity: ≥95%

Zanidatamab (Cat No.: I042217) is a bispecific monoclonal antibody that targets two distinct epitopes on the HER2 receptor, a protein overexpressed in various cancers, including breast, gastric, and biliary tract cancers. By simultaneously binding these sites, zanidatamab enhances receptor internalization and degradation, leading to stronger antitumor effects compared to traditional HER2 therapies. It also promotes antibody-dependent cellular cytotoxicity (ADCC). Currently in clinical trials, zanidatamab has shown promising efficacy and safety, particularly in HER2-positive cancers resistant to existing HER2-targeted treatments.

Reference

[1]. Weisser N, et, al. Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers. Cancer Res. 2017:77 (13).